Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Co    LLY

Delayed Quote. Delayed  - 08/25 10:01:26 pm
78.01 USD   -0.55%
08/24 ELI LILLY AND : Lilly to Participate in Morgan Stanley Global Health..
08/22DJEli Lilly, AstraZeneca Progress With Alzheimer's Drug
08/22DJELI LILLY AND : AstraZeneca Get Fast-Track Designation for Alzheimer..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Eli Lilly & Co. : Lilly to Discontinue Late-Stage Tabalumab RA Program on Lack of Efficacy

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/07/2013 | 07:59pm CEST

--Lilly to discontinue rheumatoid arthritis Phase 3 program for tabalumab

--Company will take a first-quarter charge of about $50 million

--Tabalumab continues to be in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

(Updates with additional details, share movement)

 
   By Saabira Chaudhuri 
 

Eli Lilly & Co. (LLY) said it will discontinue the rheumatoid arthritis Phase 3 program for its drug, tabalumab, citing a lack of efficacy.

The announcement comes less than two months after the drug company said it would stop one of three late-stage registration studies of tabalumab due to insufficient efficacy. At the time, Lilly said it was continuing to evaluate tabalumab in two other Phase 3 rheumatoid-arthritis registration studies as well as an open-label extension study and several smaller studies.

Lilly on Thursday said it has decided to discontinue the development of tabalumab in its current rheumatoid-arthritis program based on the outcomes of two separate interim-futility analyses. All ongoing Phase 2 and Phase 3 rheumatoid-arthritis studies will be stopped.

"While we are obviously disappointed by these results in rheumatoid arthritis, we continue to believe that tabalumab could have significant potential for patients in other disease areas," said Dr. Eiry Roberts, vice president of autoimmune product development at Lilly.

The decision is expected to result in a first-quarter charge to research-and-development expenses of about $50 million.

A spokesperson for the company noted Tabalumab is still in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

The Indianapolis company is experiencing one of the steepest patent cliffs in the drug industry, grappling with recent and looming generic competition for top-selling drugs as a result of patent expirations. The company lost exclusivity for its former No. 1 product, Zyprexa, in October 2011, and it will lose U.S. patent protection for the blockbuster antidepressant Cymbalta this December.

Lilly is trying to replenish revenue lost to generic competition for the older drugs by bringing new products to market and by increasing sales of drugs that remain patent-protected.

Last month, Lilly said its fourth-quarter earnings slipped 3.6% as the drug maker recorded weaker revenue as sales of Zyprexa slid.

Shares of Lilly, which backed its view for the year, edged down 41 cents to $53.52 in recent trading. The stock has risen 36% in the past 12 months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ELI LILLY AND CO
07:16p ELI LILLY AND : Researchers at Eli Lilly Detail Findings in Gastroenterology (As..
07:02p ELI LILLY AND : Study Data from Eli Lilly Update Knowledge of Alzheimer Disease ..
08/24 ELI LILLY AND : Lilly to Participate in Morgan Stanley Global Healthcare Confere..
08/22DJEli Lilly, AstraZeneca Progress With Alzheimer's Drug
08/22DJELI LILLY AND : AstraZeneca Get Fast-Track Designation for Alzheimer's Drug--Upd..
08/22DJELI LILLY AND : AstraZeneca Get Fast Track Designation for Alzheimer's Drug
08/22 ASTRAZENECA : Eli Lilly Get Fast Track Designation For AZD3239
08/22 ELI LILLY AND : Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD..
08/21 ELI LILLY AND : next CEO could carry first Alzheimer's treatment across the fini..
08/19 ELI LILLY AND : Assigned Patent
More news
Sector news : Pharmaceuticals - NEC
05:46p FTSE retreats as pharma stocks fall
03:56pDJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
03:12pDJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
03:11pDJStocks Fall as Investors Look to Fed's Jackson Hole Meeting -- 3rd Update
02:15pDJMylan Boosts Price Assistance for EpiPen Amid Backlash
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/24 PATENT DISPUTE ELI LILLY AND ACRUX : Update And Opportunity?
08/23 Patent Dispute Off The Rails For Eli Lilly And Acrux
08/22 Lilly and AstraZeneca's AZD3293 Fast Track'd for early Alzheimer's
08/22 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2016 Update
08/18 The 'Safest' Healthcare Top Dogs Of August?
Advertisement
Financials ($)
Sales 2016 21 147 M
EBIT 2016 4 751 M
Net income 2016 3 314 M
Debt 2016 2 807 M
Yield 2016 2,62%
P/E ratio 2016 27,08
P/E ratio 2017 21,29
EV / Sales 2016 4,23x
EV / Sales 2017 4,04x
Capitalization 86 585 M
More Financials
Chart ELI LILLY AND CO
Duration : Period :
Eli Lilly and Co Technical Analysis Chart | LLY | US5324571083 | 4-Traders
Full-screen chart
Technical analysis trends ELI LILLY AND CO
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 96,7 $
Spread / Average Target 23%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John C. Lechleiter Chairman, President & Chief Executive Officer
Derica W. Rice Chief Financial Officer & EVP-Global Services
Thomas F. Bumol Senior VP-Biotechnology & Autoimmunity Research
Timothy J. Garnett Chief Medical Officer
Jan M. Lundberg Executive Vice President-Science & Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND CO-6.91%86 585
JOHNSON & JOHNSON15.57%324 776
ROCHE HOLDING LTD.-11.47%217 694
NOVARTIS AG-9.45%213 882
PFIZER INC.7.87%211 206
MERCK & CO., INC.18.76%173 462
More Results